Andreana N. Holowatyj, PhD, MS, Details the Main Results of Research into Colorectal Cancer Disparities

Video

The lead author from a study presented at the American Association for Cancer Research Annual Meeting 2021 explained the main findings regarding potential differences in tumor mutation burden by race in patients with early-onset colorectal cancer.

In a conversation with CancerNetwork®, Andreana N. Holowatyj, PhD, MS, of the Vanderbilt University Medical Center, spoke about the main takeaways from her research presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 focusing on tumor mutation burden by race and disparities in early-onset colorectal cancer.

Transcription:

One of the things that we undertook in our analysis was to explore potential differences in tumor mutation burden by race within the population of early-onset colorectal cancer cases. And what we observed in doing so was that compared with young non-Hispanic Whites with a microsatellite stable colorectal tumor, we saw that young non-Hispanic Blacks actually had a significantly higher tumor mutation burden. However, when compared again with [non-Hispanic] Whites, there was no difference in tumor mutation burden with Asian or Pacific Islanders diagnosed with early-onset disease. Seeing this significantly higher tumor mutation burden in young [non-Hispanic] Blacks was quite striking and warranted further study.

Reference:

Holowatyj AN, Wen W, Gibbs T, et al. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases. Presented at: AACR Annual Meeting 2021. Virtual. Abstract 101.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Related Content